In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 675 ( 2022-12-14)
Abstract:
Subduing skin inflammationThe integrity of the epidermis is maintained through a continuous turnover process and involves members of the Kallikrein-related peptidase (KLK) family and their cognate inhibitor lymphoepithelial Kazal-type-related inhibitor (LEKTI). Netherton Syndrome (NS) is a debilitating skin condition caused by a LEKTI deficiency that results in unregulated activity of KLK5, KLK7 and KLK14. Chavarria-Smith et al. characterized two monoclonal antibodies that inhibited murine KLK5 and KLK7, which improved skin barrier function and reduced inflammation in a mouse model of NS as well as a mouse model of atopic dermatitis. They engineered a bispecific human anti-KLK5/KLK7 that displayed inhibitory activity by targeting an allosteric site in KLK5 distal from the active site. These findings suggest anti-KLK5/7 antibodies may be a potential strategy for treating NS and other inflammatory skin disorders.
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abp9159
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2022
Permalink